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Abstract
This paper presents a new multi-residue method for the quantification of more than 142 anthropogenic compounds of emerging
concern (CECs) in various environmental matrices. These CECs are from a wide range of major classes including pharmaceu-
ticals, household, industrial and agricultural. This method utilises ultra-performance liquid chromatography coupled with tandem
mass spectrometry (UPLC-MS/MS) for analysis of fivematrices (three liquid and two solid) fromwastewater treatment processes
and the surrounding environment. Relative recoveries were predominantly between 80 and 120%; however, due to the com-
plexity of the matrices used in this work, not all compounds were recovered in all matrices, from 138/142 analytes in surface
water to 96/142 analytes in digested solids. Method quantification limits (MQLs) ranged from 0.004 ng L−1 (bisoprolol in surface
water) to 3118 ng L−1 (creatinine in wastewater treatment work (WwTW) influent). The overall method accuracy was 107.0%,
and precision was 13.4%. To test its performance, the method was applied to the range of environmental matrices at WwTWs in
South West England. Overall, this method was found to be suitable for application in catchment-based exposure-driven studies,
as, of the total number of analytes quantifiable in each matrix, 61% on average was found to be above their corresponding MQL.
The results confirm the need for analysing both the liquid and solid compartments within aWwTW to prevent under-reporting of
concentrations.
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Introduction
The use of anthropogenic, household, industrial or agricultural
chemicals such as pharmaceuticals, pesticides, plasticisers,
UV filters, industrial chemicals and microplastics is ubiqui-
tous, and they have been recognised as a source of environ-
mental contamination. These compounds have been quanti-
fied at levels ranging from ng L−1 to μg L−1, and their impact
on the environment is not well known. These compounds are
often designed to be biologically active and can be persistent
in the environment, where they have the potential to
bioaccumulate within the tissues of organisms [1–4]. For these
reasons, among many others, they are known as compounds
of emerging concern (CECs) [5–7].
CECs are primarily introduced to the environment via point
sources such as wastewater treatment works (WwTWs), indus-
trial discharge points and landfill leachates [8–11]. Diffuse
sources, such as direct application to land in agriculture, have
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been identified as a source of select sub-classes of CECs, such as
pesticides and veterinary pharmaceuticals. Additionally, the ap-
plication of digested sludge, fromWwTW processes, directly to
the land in modern farming practices is a potential source of
other classes of CECs [12]. Bisphenol A (BPA) for instance,
has been found at high levels within this matrix [13, 14].
CECs have been detected across the world in a multitude of
environmental matrices [6, 15, 16]. This is due to their wide-
spread use and to partitioning that can occur from the aqueous
phases into suspended solids and sediments, where it can af-
fect terrestrial organisms and fauna.Whilst their presence does
not necessarily mean harm, the ecotoxicological effects of
many of the CECs have been quantified in laboratory-based
studies for a variety of different organisms across trophic
levels and toxic effects have been demonstrated [17–19].
These laboratory-based ecotoxicological studies broadly fo-
cus on a single compound versus a single organism, but the
environment is a ‘cocktail’ of CECs and different microorgan-
isms. Ermler et al. [20] addressed this lack of knowledge for
anti-androgens and found that concentration addition is a good
model for predicting the effect of mixtures for up to six com-
pounds. Leading on from this work, Orton et al. [21] tested
multi-component mixtures of up to 30 compounds with vary-
ing mixture ratios. At the point where one mixture caused a
10% inhibition of the cancer cell assay, the concentrations of
the components were a factor of 5.8 lower than the concentra-
tion that would be needed for them to individually cause this
effect [21]. This highlights the need for current analytical
methods to have method quantification limits (MQLs) lower
than the no-observed effect concentrations (NOECs) of indi-
vidual CECs, to enable accurate measurements of very low
concentrations, for a better understanding of the risk they pose
to the environment in combination.
Work is being done to further understand the fate, behav-
iour and effect of CECs within our environment. However, the
sheer number of them and their everchanging usage makes
this a challenge. The European Inventory of Existing
Commercial Chemical Substances (EINECS) contains over
100,000 substances [22], with further substances being regis-
tered across all EEA countries, through Registration,
Evaluation, Authorisation and Restriction of Chemicals
(REACH). Currently, there are 94,705 registrations containing
22,257 substances, or 22,096 unique substances that are in use
[23]. This number is increasing every year, as new substances
are developed and registered, and this pattern can be found
across all classes of CECs.
The exponential growth of populations across the world, due
to increased life expectancy and decreased infant mortality, is
increasing the usage of pharmaceuticals. This puts further pres-
sure on agriculture to produce food faster and cheaper, often via
the use of pesticides, herbicides and other anthropogenic com-
pounds. With the number of CECs in use, and more being
developed each year, it is not feasible to determine the exposure
and effects of all these compounds in a single catchment,
let alone across a country or continent. To further complicate
matters, many CECs degrade through different processes such
as hydrolysis, photolysis and metabolism. These form transfor-
mation products and metabolites, which are often more harmful
than the parent compounds [24].
Brack et al. [25] conducted a review of the EU Water
Framework Directive (WFD) and concluded that there are spe-
cific challenges both at European scale and at a local scale.
Regulation and national monitoring schemes such as the WFD
and the UK Chemical Investigations Programme (CIP) are suit-
able for furthering the understanding of this problem on a wider
scale. Through identification and assessment of the most wide-
spread CECs, high-risk compounds can be identified and man-
aged through harmonised methods across diverse areas.
However, they are often limited by the sampling method, i.e. a
few samples collected at many locations, using only grab sam-
ples, which are not very representative [26]. Sampling at a local
scale is crucial to determine catchment-specific substances and
mixtures that might be a specific problem in the local environ-
ment. This can allow more targeted management of risks and
hazards at local catchment level. There is a further need for
analytical methods which can detect CECs down to, or below,
the predicted no-effect concentration (PNEC), as this will allow
a more adequate risk assessment [27].
To gain a better understanding of the fate of CECs within
an environmental catchment, analysis of the influent and ef-
fluent of contributing WwTWs is required, including analysis
of solid particulate matter (SPM) and digested solids, as well
as corresponding surface water. Overall, in the literature, there
is still a lack of multi-residue methods for quantification of
CECs in solid matrices. Even fewer publications consider both
the liquid and solid phases in the WwTWor the environment.
Many studies focus specifically on pharmaceuticals, personal
care products, industrial chemicals, veterinary pharmaceuti-
cals or pesticides. However, a catchment potentially contains
compounds from a variety, if not all, classes of CECs, though
it is rare that they are all the focus of analysis in a single
campaign. One study by Gustavsson et al. [28] covers many
different classes of CEC, leading to the analysis of 172 com-
pounds; however, this was only achieved through multiple
sample preparation methods. For a comprehensive under-
standing of the exposure and environmental risk of chemical
mixtures, multi-residue quantitative methods covering a large
variety of CECs are required.
The aim of this work is to develop and validate a new multi-
residue method (< 190 compounds including internal standards)
for a wide range of CECs prioritised for risk assessment at a
catchment scale, and accounting for the highly urbanised and
agricultural areas of one catchment. The classes of CECs covered
by this method include the following: UV filters, parabens,
plasticisers, steroid estrogens, antibacterials/antibiotics, antifun-
gals, hypertension drugs, non-steroidal anti-inflammatory drugs
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(NSAIDs), lipid regulators, antihyperlipidaemics, antihyperten-
sives, antihistamines, drugs for erectile dysfunction, drugs for
diabetes, cough suppressants, beta blockers, H2 receptor ago-
nists, X-ray contrast media, drug precursors, anticancer drugs,
anaesthetics, antidepressants, anti-epileptics, calcium channel
blockers, hypnotics, antipsychotics, drugs for dementia, human
indicators, analgesics, stimulants, opioids, drugs used in veteri-
nary medicine, pesticides, fungicides and herbicides and metab-
olites. The selection of analyte groups was based not only on
prioritisation including existing and proposed legislation,
European and national watch lists (UKWIR CIP, EU Watch
List) [29–32] and the literature [33, 34] but also on exploring
usage statistics (NHS prescriptions [35]), entry into the environ-
ment (metabolism, excretion from DrugBank [36]), persistence,
bioaccumulation, transport throughout the environment and tox-
icity of organisms [mammals, aquatic and benthic (log Kow, log
Koc, logDow, water solubility, vapour pressure, Henry’s law con-
stant, bioconcentration factor, EPI Suite, ACD/Labs [37, 38])].
Materials and methods
This paper provides an expanded and broader scope method
based on the method published by Petrie et al. [39]. Electronic
Supplementary Material (ESM) Table S1 contains data on the
suppliers of the compounds as well as their physiochemical
properties.
The analytes were primarily purchased in solid form, be-
fore being accurately weighed and dissolved in HPLC grade
methanol (MeOH) (Sigma-Aldrich), or other suitable sol-
vents, at a concentration of 1.0 mg mL−1. These stock solu-
tions were stored in silanised glass vials in the dark at − 20 °C,
unless otherwise stated. Multi-analyte mixtures were prepared
from these stock solutions. The CECs, their corresponding
internal standards, data acquisition method andMS/MS detec-
t ion parameters can be found in ESM Table S2.
Chromatograms of all analytes can be found in ESM Fig. S1.
The internal standards 1S,2R-(+) ephedrine-d3, amphet-
amine-d5, benzoylecgonine-d8, cocaethylene-d8, cocaine-d3,
codeine-d6, cotinine-d3, 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrroloidine-d3 (EDDP-d3), estradiol (2,4,16,16-d4),
estrone (2,4,16,16-d4), heroin-d9, ketamine-d4, 3,4-
methylenedioxyamphetamine-d5 (MDA-d5), 3,4-
methylenedioxymethamphetamine (MDMA-d5), mephedrone-
d3, methadone-d9, methamphetamine-d5, methylparaben-13C,
morphine-d3, norketamine-d4, quetiapine-d8 and tempazepam-
d5 were purchased from LGC Standards (Middlesex, UK).
Amitrpityline-d3, amoxicillin-d4, capecitabine-d11, ciprofloxa-
cin-d8, citalopram-d6, diazepam-d5, erythromycin-13C,d3, flu-
oxetine-d5, gabapentin-d4, imidacloprid-d4, metazachlor-d6,
metoprolol-d7, mirtazapine-d3, norsertraline-d4, nortriptyline-
d3, ofloxacin-d3, oxazepam-d5, sildenafil-d8 and verapamil-d7
were purchased from Toronto Research Chemicals (TRC)
(Toronto, Canada). Acetaminophen-d4, atenolol-d5, bisphenol
A-d16, carbamazepine-13C6, ibuprofen-d3, ketoprofen-d3,
metformin (dimethyl-d6), methiocarb-d3, naproxen-d3, pro-
pranolol-d7, sertraline-d3 and tamoxifen-13C2,15N were pur-
chased from Sigma-Aldrich (Gillingham, UK), and
bezafibrate-d6 was purchased from QMX Laboratories
(Thaxted, UK). These were purchased as solutions at a concen-
tration of 0.1 mg mL−1 or 1.0 mg mL−1 in methanol or other
appropriate solvents. If no solutionswere available, 1.0mg pow-
der was purchased, and the entire contents of the vial were
dissolved in methanol. The MS/MS detection parameters for
the internal standards can be found in ESM Table S3.
All glassware in this paper was silanised to prevent the
analytes and internal standards from absorbing to the surface.
This was done by coating the internal surfaces of the glass-
ware with 5% dimethylchlorosilane (DMDCS) in toluene
(Sigma-Aldrich), rinsing with toluene (Sigma-Aldrich) twice,
then rinsing again with MeOH three times, and leaving to dry
between each coating or rinse.
Methods for sample collection
Sampling was carried out in a river catchment in South
West England. Sampling involved collection of samples
from all major WwTWs and receiving environmental wa-
ters. Twenty-four-hour composites using a 3700 ISCO
sampler (RS Hydro) were collected for both influent and
effluent wastewaters in each case. Grab samples were
utilised in surface water samples. SPM was collected from
influent samples.
SPM per litre was calculated by filtering 30 mL through a
pre-dried and pre-weighed GF/F glass microfibre filter. This
was then re-dried at 105 °C for 8 h, left to cool and re-weighed
to quantify SPM in grams per litre. Data are shown in ESM
Table S4. Digested sludge was collected on three consecutive
days, both directly after digestion and prior to disposal. Data
are shown in ESM Table S5.
All samples were kept on ice during sampling (ice was
placed within the composite sampler to maintain a cool tem-
perature of 0–4 °C and promote stability) or placed in a cool
box and kept on ice until the samples were transported to the
lab. Once at the lab, samples for liquid analysis were trans-
ferred to 125-mL PPE bottles (Fisherbrand) and frozen (−
20 °C) for further preparation and analysis at a later date.
For the influent samples, the remainder of the sample was
filtered to collect the SPM, which was then frozen (− 20 °C).
Most compounds do not adsorb to the PPE bottles, with very
few exceptions (ESM Table S6).
Methods for extraction and analysis
The methods used for sample preparation of both liquid
and solid matrices, as well as their analysis, can be found
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in Fig. 1; this is also discussed in more detail below.
Development of an extraction method for liquid matrices
with hydrophilic-lipophilic-balanced solid-phase extrac-
tion (HLB SPE) was developed based on the method pub-
lished by Kasprzyk-Hordern et al. [40]. The microwave-
assisted extraction (MAE) for solid matrices was devel-
oped based on the method published by Petrie et al. [39].
Extraction for liquid matrices
The samples were filtered with a GF/F glass fibre filter
(0.7 μm) (Whatman, Sigma-Aldrich) and adjusted to
pH 7.5–8.5. 50 mL of influent or effluent (100 mL surface
water) was accurately measured and spiked with 50 μL of
1 μg mL−1 (50 ng) internal standard mixture in MeOH.
The 60-mg HLB SPE cartridges (OASIS, Waters, UK)
were conditioned and equilibrated with 2 mL of MeOH,
followed by 2 mL of deionised water (H2O) at a rate of <
1 mL min−1 (under gravity). The deionised H2O was ob-
tained from a Milli-Q system (18.2 MΩ). The sample was
loaded at 5 mL min−1 before the cartridges were dried
under vacuum. Analytes were eluted using 4 mL MeOH
at 1 mL min−1 (under gravity). Once eluted, the extracts
were evaporated to dryness at 40 °C, with a steady flow
of nitrogen using a TurboVap LV concentration worksta-
tion. Finally, the samples were reconstituted in 500 μL of
80:20 H2O:MeOH, mixed thoroughly to ensure completed
dissolution and transferred to LC vials (polypropylene)
(Waters, UK).
Extraction for solid matrices
The solid samples, digested sludge and SPM were initially fro-
zen and freeze-dried (ScanVac, CoolSafe freeze dryer, Lynge,
Denmark). The freeze-dried samples were homogenised, and
0.25–0.5 g was weighed out and spiked with 50 μL of
1 μg mL−1 (50 ng) internal standard mixture in MeOH. This
was left for 30 min to 1 h, for the methanol to evaporate off.
The samples were then transferred to MAE perfluoroalkoxy
(PFA) tubes with 25–30 mL of 50:50 acidified H2O
(pH 2):MeOH. The MAE tubes were placed in 800 W MARS
6 microwave (CEM, UK). The temperature was ramped to
110 °C, over 10 min, then held at this temperature for 30 min,
before allowing the samples to cool. SPE was then carried out
using 60-mg mixed-mode cationic exchange (MCX) cartridges
(Oasis, Water, UK). These were conditioned and equilibrated
using 2 mL MeOH and 2 mL acidified H2O (pH 2) at <
1 mL min−1 under gravity. The samples were then loaded at
5 mL min−1 and dried under vacuum. Once dried, the acid
analytes were eluted first with 2 mL of 0.6% formic acid
(HCOOH) (Sigma-Aldrich) in MeOH. The basic analytes were
eluted secondwith 3mL of 7% ammoniumhydroxide (NH4OH)
Fig. 1 Flow chart from sample
preparation to analysis, for
analysis of liquid and solid
samples by ESI− and ESI+
methods
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in MeOH (Sigma-Aldrich). These extracts were evaporated to
dryness at 40 °C, with a steady flow of nitrogen using a
TurboVap. The residue was reconstituted in 500 μL of 80:20
H2O:MeOH, mixed thoroughly to ensure completed dissolution
and transferred to LC vials.
Analysis of samples
The analytes were separated by UPLC performed on theWaters
ACQUITY UPLC™ system (Waters, UK). The column used
was a reversed-phase C18 column (Waters, UK), 150 mm×
1.0 mm, with a particle size of 1.7 μm. The samples were
analysed with Xevo Triple Quadrupole (TQD) Mass
Spectrometer (Waters, UK), equipped with an electrospray
ionisation (ESI) source in positive and negative modes. To op-
timise ionisation, two different sets of parameters were used for
the ESI-positive and ESI-negative modes. The parameters for
these can be seen in Fig. 1. The systems were controlled using
MassLynx (Waters, UK). Argon (99.998%) gas, supplied by a
BOC cylinder, was used as a collision gas. The nebulising gas
was nitrogen, provided by a high-purity nitrogen generator
(Waters, Manchester, UK). Two mobile phases were used in
the gradient mode ESI+: mobile phase A contained 80:20
H2O:MeOH with 5 mM ammonium acetate (NH4OAc) and
3 mM acetic acid (CH3COOH) (pH 4.7), and mobile phase B
contained 100% MeOH. Starting conditions were 100% A,
decreasing to 10% A over 20 min, maintained at this level for
6 min, before increasing back to 100%A over 0.5 min and held
for 7.5min to return the column to equilibrium; in ESI−: mobile
phase A contained 80:20 H2O:MeOH with 1 mM ammonium
fluoride (NH4F) and mobile phase B, which was 5:95
H2O:MeOH containing 1 mM NH4F. The gradient began at
100% A for 0.5 min and reduced to 40% A over 2 min, before
being further reduced to 0% A over the next 5.5 min. It was
held at 0% A for 6 min before increasing back up to 100% A
over 0.1 min. This was maintained for 8.4 min to re-equilibrate
the column. The HPLC grade MeOH, NH4OAc (Fluka) and
CH3COOH were obtained from Sigma-Aldrich (Gillingham,
UK). The NH4F (Fluka) was obtained from Fisher Scientific
(Loughborough, UK) and deionised water (18.2 MΩ) obtained
from a Milli-Q system. The temperature of the built-in sample
manager was 4.0 °C with an injection volume of 20 μL. The
mobile phases were run at a rate of 0.04mLmin−1, as a gradient
of a high ratio of aqueous (80%) to 100% MeOH in both pos-
itive and negative ionisation modes. The exact gradients and
composition of the mobile phases can be also seen in Fig. 1.
Data processing was carried out using TargetLynx software,
which is an extension to MassLynx (version 4.1, Waters).
Instrument performance
To quantify the analytes, an internal standard approach with an
18-point calibration curve was used. For the majority of the
compounds, the analysed range covers 6 orders of magnitude,
from ng L−1 to mg L−1. Each point was repeated every 24 h over
3 days. These calibration samples were prepared in a ratio of
80:20 H2O:MeOH unbuffered solutions. The signal-to-noise ra-
tios of these samples were used to determine the concentration
of the instrument detection limit (IDL) and instrument quantifi-
cation limit (IQL), where S/N ≥ 3 or S/N ≥ 10, respectively.
Determination coefficients (r2) were calculated for the full linear
range (IDL to ≤ 1000 μg L−1). Inter- and intra-day precision and
accuracy were calculated from repeated injections, at regular
intervals (n = 3) of three concentrations (10 μg L−1,
100 μg L−1, 500 μg L−1) in 80:20 H2O:MeOH, across 24 h
(intra-day) and across 72 h (inter-day).
Method performance
As SPE was used as a preconcentration and clean-up step, the
recovery of each analyte must be assessed. Absolute and rel-
ative recoveries for SPE of liquid matrices were calculated
from matrices spiked in duplicate (n = 2) at three concentra-
tions for A-ESI+ (100 ng L−1, 1000 ng L−1 and 5000 ng L−1
for effluent and influent, and 50 ng L−1, 500 ng L−1 and
2500 ng L−1 for surface water). For B-ESI+ and C-ESI−, the
matrices were spiked at two concentrations (100 ng L−1 and
1000 ng L−1 for effluent and influent, and 50 ng L−1 and
500 ng L−1 for surface water). For influent suspended partic-
ulate matter (SPM) and digested sludge (DS), the absolute and
relative recoveries take into account MAE and SPE. The sam-
ples were spiked at 50 ng g−1 and 100 ng g−1.
Method detection limits (MDLs) and MQLs were calculat-
ed using Eq. 1
MDL ¼ IDL 100
Rec Cf ð1Þ
where IDL is the instrumental detection limit, which is
calculated as discussed in the section “Method performance”;
100 is the conversion factor for recovery of a specific matrix
(Rec); and Cf is the concentration factor for the specific liquid
matrix, e.g. 200 for surface waters or 100 for effluent of efflu-
ent. For solid matrices, Cf is replaced with a conversion factor
of 2, which converts the volume into grams, based on the
0.25 g of solid matrix being extracted into a 0.5-mL vial for
analysis. MQL is calculated with the same equation but by
replacing IDL with IQL.
Furthermore, the accuracy and precision of the overall
method, including SPE, are also required. These were calcu-
lated from samples of 3 matrices taken from 5 different
WwTWs in the South West UK. These samples were spiked
at 100 ng L−1 and 1000 ng L−1 for influent and effluent sam-
ples and at 50 ng L−1 and 500 ng L−1 for surface water for A-
ESI+ and at 100 ng L−1 for all matrices for B-ESI+ and C-ESI
−. The accuracy of the method was determined from the
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percentage deviation from the known concentration of analyte
added to the sample. Precision was calculated as the relative
standard deviation (RSD) of the replicates.
It has been found that complex matrices such as in-
fluent can affect the detection of analytes, especially
when these samples have undergone SPE with HLB
cartridges, as these cartridges extract a huge range of
compounds. Therefore, matrix suppression was deter-
mined for the liquid matrices, which were extracted by
employing a method using this approach. Samples for
calculating matrix suppression were prepared by spiking
samples with 50 μL of 1 μg mL−1 of internal standards,
after the elution step of SPE, and prior to evaporation
and reconstitution. Once analysed, matrix suppression
for each analyte was calculated using the following
equation:
Matrix suppression ¼ 1− PA in SS−PA in US
PA in MP QC
 
ð2Þ
where PA is the peak area of the analyte in spiked sample
(SS), unspiked sample (US) and mobile phase quality control
(MP QC) sample.
All matrices used were collected via grab sampling and
homogenised, and all analyses were carried out on this single
sample to ensure consistent results. Due to the use of these
environmental matrices and the potential presence of analytes
within the matrices prior to spiking, the ‘blank’ or unspiked
(with analytes) portion of the sample was spiked with internal
standards and analysed to confirm the concentration of analytes,
prior to spiking, for recoveries and matrix effect analysis.
Quality control
Quality control samples were analysed before and after each
batch at three concentrations (10 μg L−1, 100 μg L−1,
500 μg L−1) along with procedural blanks, to ensure the meth-
od and instrumental performance and to monitor for contam-
ination of the equipment.
All samples were spiked with the internal standards listed
in ESM Table S3, for accurate quantification, and to account
for loss from the point of spiking until analysis and to limit
matrix effects.
Results and discussion
This paper provides an expanded and broader scope method
based on a method published by Petrie et al. [39], enabling the
analysis of household and agricultural chemicals whilst
utilising one sample preparation protocol and comprehensive
UPLC-MS/MS methodology.
UPLC-MS/MS method
All analytes were analysed using MRM and ESI− and ESI+
modes and conditions previously selected by Petrie et al. [39].
Following EU guidelines, twoMRM transitions were used for
most of the 195 compounds (142 analytes and 53 ISTDs).
This is except for cefalexin, ketoprofen, diclofenac, ibuprofen,
1,7-dimethylxanthine and norfluoxetine, which are to be con-
sidered as semi-quantitative. For ESI−, the parent ion [M−H]−
was selected, and for ESI+ mode, [M−H]+ was selected. The
most abundant daughter ion was used for quantification and
the second most for confirmation. ESM Table S2 includes the
MRMs for all analytes, the acquisition method was used to
analyse them and the assigned internal standard. The MRMs
for the internal standards can be found in ESM Table S3.
The reversed-phase BEH C18 column provided good sep-
aration and sensitivity for all compounds. These conditions
achieved good separation and peak shape for most analytes.
Further information can be found in Fig. 1. A more acidic
mobile phase was also trialled in the ESI+ method, and al-
though the peak shape and separation for the acidic com-
pounds, particularly the fluoroquinolones, were improved
slightly, they only benefitted a small number of compounds
and had a detrimental effect against many others. Satisfactory
separation of analytes was achieved within a < 40-min reten-
tion time.
Quality control criteria as recommended by the EU direc-
tive [41] utilised quality control samples, standard tolerances
of ion ratio, chromatographic retention time, relative retention
time and signal-to-noise ratio.
Instrument performance
The instrument performance was assessed by considering lin-
ear response, inter- and intra-day precision and accuracy and,
finally, instrumental detection and quantification limits. This
data can be found in Table 1.
For the linear response, a linear range covering several
orders of magnitude with the r2 value of ≥ 0.997 was ideal.
However, for a few analytes (triclosan, benzoylecgonine and
mirtazapine), this could only be achieved through splitting the
linear range into two overlapping ranges, each with the r2
value ≥ 0.997. This allowed adequate quantification across
the entire range. Of the 142 compounds, 120 have r2 values
≥ 0.997. Twenty-one of the remaining compounds have r2
values ≥ 0.992. Although this is not ideal, it is still adequate
for accurate quantification, as the other parameters indicate.
Chlorpyrifos has the lowest r2 value, likely due to the lack of
an analogous internal standard; however, it passes further in-
strumental performance criteria.
The intra-day instrumental performance is high across
many compounds. Out of the 142 analytes, the majority of
which are very precise, with a deviation of ≤ 5%. The

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Multi-residue ultra-performance liquid chromatography coupled with tandem mass spectrometry method for...
precision of 20 compounds was between 5 and 10%, and only
one compoundwas > 10% (chlorpyrifos (11.8%), likely due to
poor r2). However, all deviations are inside the recommended
maximum of 20%. For 119/142 compounds, the accuracy lay
within the ideal range of 90–110%. Of the remaining com-
pounds, only triclosan has an inaccuracy of > 20%.
Regarding the inter-day instrumental performance, the pre-
cision is high across many analytes with 115 analytes with a
deviation of ≤ 5%. Of the 27 analytes with > 5% deviation,
only 8 were > 10%. The inter-day accuracy of these com-
pounds was also high, with only 20 compounds that deviated
from the QC by > 10%, 4 of which were only slightly greater
than 20%. Data for both intra- and inter-day precision and
accuracy can be found ESM Table S7.
IDLs ranged from 0.4 ng L−1 (bisoprolol) to 4783 ng L−1
(cefalexin), and IQLs ranged from 1.2 ng L−1 (bisoprolol) to
15,940 ng L−1 (cefalexin). Whilst many of these IQL concen-
trations are very low, the samples may still need to be concen-
trated (utilising SPE), as the concentrations of most com-
pounds in environmental matrices are likely to be even lower.
Method performance
Sample extractionwas carried out using SPE following themeth-
od shown in Fig. 1 (sections “Extraction for liquid matrices” and
“Extraction for solid matrices”) and has shown good extraction
performance formanyCECs. TheOasis HLB sorbent is essential
to multi-residue methods, as it has the ability to retain a large
range of polar analytes at neutral pH and is therefore widely used
in analysis of environmental matrices. However, two drawbacks
have been found in the use of this sorbent. Firstly, HLB might
result in low recovery of very polar compounds such as metfor-
min and creatinine. This is easily remedied, as metformin and
creatinine along with acetaminophen, nicotine, caffeine and 1,7-
dimethylxanthine are present in the environment as such high
levels that direct injection are utilised instead. The second draw-
back of HLB is its lack of selectivity. Whilst enabling the extrac-
tion of a large variety of polar analytes, in complex matrices,
much of the matrix can be extracted along with the chosen
analytes, causing significant signal interference. It is therefore
important to assess matrix suppression. Previously, it was found
that the use of HLB with digested solids provided poor results.
This not only necessitated the use of an alternative sorbent,
MCX, but also splitting the eluents into acidic and basic fractions
(see Fig. 1) [39].
Figure 2 shows relative recoveries for all matrices: surface
water, effluent, influent, SPM and digested solids. These very
different matrices exhibit similar ranges of relative recovery.
Most of the compounds had recoveries between 80 and 120%.
Due to the complexity of environmental matrices, not all com-
pounds were recovered adequately across all matrices; therefore,
the number of compounds accurately quantifiable in each matrix
varies from 138 analytes in surface water to 96 analytes in
digested solids. The data for relative and absolute recoveries for
all matrices can be found in ESM Tables S8 and S9 and Fig. S2.
Matrix suppression was analysed for liquid matrices (see
Fig. 3 and ESM Table S10). Proximity to zero shows limited
matrix effects. Most analytes experienced matrix suppression,
shown in Fig. 3 as a positive percentage. For all matrices, at least
108 analytes were below 70% suppression. However, a few
compounds, primarily from ESI−, experienced significant (>
20%) signal enhancement. Some compounds experienced signal
enhancement in some matrices and suppression in others
(naproxen, erythromycin, EE2, bicalutamide, candesartan
cilexetil, gemfibrozil, chlorpyrifos). This considerable variation
is to be expected for a multi-residue method with this variety of
analytes. It especially highlights the importance of using relevant
analogous internal standards, as well as thoroughly exploring the
different matrices relevant to this work.
The method accuracy of the method was 107.0%, and the
precision was 13.4%. MQLs for liquid matrices range from
0.004 ng L−1 for bisoprolol, in surface water, to 3118 ng L−1
for creatinine, in influent (Table 2). For the remaining analytes,
there is not enough environmental data on their presence in the
UK to comment on whether the MDLs and MQLs are low
enough to measure these levels in the catchment of interest.
Therefore, this method was applied to five different matrices at
a WwTW in the South West UK, which were influent, effluent,
surface water, SPM and digested solids, to underline the
utilisation of this method to relevant environmental matrices.
Overall, this method provides a clear benefit when used in a
catchment-based study, compared to more complex approaches
with multiple sample preparation and analytical methods for
different classes of CECs from the same matrices. The main
advantage of the multi-residue method presented in this paper
is the applicability of this method to liquid and solid matrices. In
particular, SPM,which is an often forgotten but critical aspect of
wastewater, as it contains many more hydrophobic compounds
at significant concentrations within this matrix [28, 42, 43].
Application to environmental matrices
The data is presented as average concentrations with variation
across a week (Table 3 and ESMTables S11–S15). As expected,
the liquid influent fraction shows the highest variation in con-
centrations both across theweek and between different CECs. Of
the 138 analytes of this method, 70% were quantified in influent
at this site. Creatinine had the highest average concentration of
any analyte in this study (1.3 ± 0.3 mg L−1) and is often used a
human indicator due to its correlation to population [44, 45].
Other human indicators were present at high levels throughout
the week. The other CECs were present at a range of concentra-
tions. Methiocarb, for example, is present intermittently across
the week with an average concentration of 3.7 ± 0.6 ng L−1,
which is very close to its MQL of 0.86 ng L−1. However, acet-
aminophen reaches concentrations several magnitudes higher
Proctor K. et al.
than methiocarb, at 393.6 ± 100.0 μg L−1. This is slightly higher
than those published in a review by Verlicchi et al. [11] which
had an absolute highest concentration of 246 μg L−1. It is inter-
esting to see the presence of the (pesticide) methiocarb in
Digested solids SPM Influent Effluent Surface water

















































































































































Fig. 2 Relative recoveries for all matrices. Error bars show the range of standard deviation
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Fig. 3 Matrix suppression for all liquid matrices. Error bars show the range of standard deviation
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Table 2 Method performance data for ECs of interest in the mobile phase (ordered by class)










MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
UV filter Benzophenone-1 0.07 0.35 0.14 0.71 0.23 1.15 0.004 0.02 0.14 0.70
Benzophenone-2 0.16 0.79 0.34 1.68 0.36 1.82 0.004 0.02 0.09 0.44
Benzophenone-3 0.15 0.77 0.19 0.97 0.37 1.87 – – – –
Benzophenone-4 2.09 6.90 5.78 19.1 7.83 25.8 0.21 0.70 4.01 13.2
Parabens Methylparaben 0.08 0.40 0.19 0.94 0.28 1.41 0.003 0.02 0.06 0.31
Ethylparaben 0.24 0.79 0.46 1.52 0.49 1.61 0.01 0.05 0.17 0.57
Propylparaben 0.25 0.83 0.47 1.54 0.63 2.08 0.01 0.03 0.22 0.72
Butylparaben 0.08 0.38 0.14 0.71 0.24 1.21 0.002 0.01 0.10 0.52
Plasticizer Bisphenol A 0.26 0.86 0.56 1.84 0.85 2.79 0.03 0.09 0.27 0.88
Steroid estrogens E1 0.78 3.92 0.15 7.69 1.96 9.78 0.04 0.21 1.68 8.38
E2 0.90 4.48 1.41 7.03 1.84 9.22 0.04 0.21 1.48 7.41
EE2 0.98 4.91 1.46 7.32 1.83 9.15 – – – –
Antibiotics and
antibacterials
Sulfasalazine 4.31 14.2 9.66 31.9 12.6 41.4 – – – –
Clarithromycin 0.18 0.90 0.28 1.40 0.34 1.69 – – – –
Azithromycin 0.08 0.26 0.21 0.68 0.14 0.45 0.03 0.10 0.01 0.04
Trimethoprim 0.26 0.85 0.51 1.67 0.73 2.41 0.01 0.03 0.07 0.22
Sulfamethoxazole 0.19 0.63 0.47 1.56 0.72 2.38 0.02 0.08 0.12 0.41
Triclosan 2.93 9.68 4.55 15.0 4.93 16.3 – – – –
Amoxicillin – – 0.26 0.86 – – – –
Metronidazole 0.29 0.98 0.68 2.27 0.57 1.90 0.03 0.09 0.03 0.10
Sulfadiazine 0.05 0.18 0.18 0.59 0.18 0.62 0.003 0.01 0.003 0.01
Cefalexin 35.6 118.7 10.2 33.9 18.9 63.1 – – – –
Ofloxacin 0.35 1.17 0.72 2.40 0.58 1.93 – – – –
Ciprofloxacin 1.85 6.17 5.10 17.0 3.48 11.6 – – – –
Tetracycline 0.15 0.50 0.30 1.01 0.18 0.59 – – – –
Danofloxacin 1.58 5.28 4.45 14.85 3.62 12.08 – – 2.84 9.45
Oxytetracycline 6.04 20.1 10.1 33.6 8.26 27.5 – – – –
Chloramphenicol 3.18 10.6 6.52 21.7 4.21 14.0 0.21 0.69 0.15 0.48
Penicillin G 0.89 2.98 – – – – – – – –
Penicillin V 0.56 1.86 0.92 3.06 2.40 8.00 0.84 2.80 – –
Erythromycin 1.15 3.83 2.35 7.85 2.22 7.41 – – – –
Prulifloxacin – – 51.3 171.0 35.3 117.6 – – – –
Norfloxacin 0.01 0.04 0.02 0.06 0.02 0.07 – – – –
Antifungal Griseofulvin 0.32 1.06 0.52 1.74 0.59 1.98 0.05 0.16 0.06 0.21
Ketoconazole 0.06 0.21 0.03 0.10 0.04 0.12 0.02 0.07 0.00 0.01
Hypertension Valsartan 2.81 9.26 6.40 21.1 7.24 23.9 – – – –
Irbesartan 0.89 4.47 1.88 9.38 2.50 12.5 – – – –
Lisinopril 2.17 21.7 4.25 42.5 3.25 32.5 0.04 0.43 0.25 2.47
NSAIDs Ketoprofen 0.74 3.72 1.60 8.00 2.38 11.9 0.06 0.28 0.47 2.35
Ibuprofen 0.06 0.31 0.08 0.42 0.19 0.93 0.005 0.02 0.07 0.36
Naproxen 0.61 3.07 1.17 5.85 6.29 31.5 0.05 0.25 0.60 3.02
Diclofenac 0.22 0.73 0.44 1.44 0.67 2.22 0.02 0.06 0.75 2.46
Acetaminophen 1.20 6.02 2.39 12.0 138.0* 1017* 0.04 0.21 2.74 13.7
Lipid regulator Bezafibrate 0.22 0.66 0.38 1.25 0.64 2.11 0.02 0.05 0.18 0.60
Atorvastatin 0.14 0.70 0.17 0.84 0.17 0.85 – – – –
Antihyperlipidemic Gemfibrozil 0.30 1.00 0.63 2.11 1.12 3.75 – – 0.20 0.67
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Table 2 (continued)










MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
Antihyperintensive Candesartan Cilexetil 6.89 23.0 – – – – – – – –
Antihistamine Fexofenadine 0.21 0.69 0.40 1.32 0.56 1.85 – – – –
Cetirizine 0.26 0.87 0.32 1.06 0.52 1.72 – – – –
GUD/ED Sildenafil 0.01 0.03 0.02 0.05 0.01 0.05 0.001 0.003 0.001 0.003
Diabetes Metformin 156.0* 515.0* 163.0* 460.0* 457.0* 1509* – – – –
Gliclazide 0.15 0.77 0.16 0.82 0.22 1.09 – – – –
Sitagliptin 0.03 0.09 0.08 0.27 0.06 0.22 0.004 0.01 0.003 0.01
Cough suppressant Pholcodine 2.25 7.42 8.02 26.5 25.3 83.3 0.28 0.92 1.52 5.00
Beta blocker Atenolol 0.20 0.66 0.56 1.84 0.71 2.35 0.01 0.05 0.10 0.33
Metoprolol 0.07 0.35 0.19 0.96 0.28 1.40 0.01 0.03 0.03 0.14
Propranolol 0.29 0.96 0.73 2.41 0.68 2.25 0.01 0.04 0.13 0.42
Bisoprolol 0.001 0.004 0.004 0.01 0.003 0.01 0.0001 0.0005 0.0001 0.0005
H2 receptor agonist Ranitidine 7.96 39.8 22.3 111.4 14.8 73.8 0.44 2.19 4.81 24.1
Cimetidine 1.60 7.98 3.12 15.6 5.06 25.3 – – – –
X-ray contrast
media
Iopromide 5.97 29.9 14.1 70.6 24.5 123.0 – – – –
Various Buprenorphine 0.06 0.20 0.11 0.36 0.18 0.61 0.02 0.07 0.01 0.05
Drug precursor Ephedrine/pseudoephedrine 0.60 1.97 1.62 5.36 1.32 4.36 0.02 0.07 0.11 0.35
Norephedrine 0.18 8.82 0.35 17.3 0.37 18.6 0.01 0.39 0.04 1.85
Anticancer Azathioprine 0.17 0.55 0.36 1.20 0.41 1.36 – – – –
Methotrexate 6.13 20.2 9.04 29.8 7.11 23.5 0.16 0.53 1.64 5.42
Ifosfamide 0.08 0.40 0.24 1.22 0.31 1.53 – – – –
Tamoxifen 14.5 72.6 0.76 3.82 0.70 3.50 0.004 0.01 2.23 11.14
Imatinib 0.88 2.93 1.13 3.76 1.78 5.95 0.10 0.35 0.06 0.21
Capecitabine 0.01 0.02 0.01 0.03 0.01 0.03 0.002 0.01 0.001 0.003
Bicalutamide 0.22 0.72 0.31 1.02 0.32 1.07 0.02 0.06 0.01 0.03
Anaesthetic and
metabolite
Ketamine 0.07 0.37 0.19 0.93 0.24 1.20 0.005 0.02 0.03 0.17
Norketamine 0.23 0.76 0.56 1.86 0.72 2.37 0.02 0.05 0.10 0.33
Venlafaxine 0.07 0.37 0.24 1.20 0.37 1.83 0.01 0.03 0.08 0.38
Desmethylvenlafaxine 0.24 0.80 0.66 2.18 0.85 2.79 0.01 0.05 0.09 0.29
Fluoxetine 1.14 5.71 1.42 7.08 0.50 2.52 0.005 0.02 0.11 0.53
Norfluoxetine 1.64 8.21 1.27 6.35 0.42 2.12 0.004 0.02 0.14 0.68
Sertraline 1.61 8.07 1.21 6.05 0.74 3.72 0.002 0.01 0.17 0.86
Mirtazapine 0.09 0.44 0.25 1.25 0.39 1.94 0.01 0.03 0.05 0.27
Citalopram 0.61 6.08 1.41 14.1 1.24 12.4 0.02 0.24 0.16 1.64
Desmethylcitalopram 0.14 0.69 0.36 1.82 0.31 1.54 0.01 0.03 0.05 0.24
Paroxetine 0.18 0.59 0.21 0.69 0.13 0.45 0.01 0.02 0.005 0.02
Duloxetine 0.04 0.13 0.05 0.18 0.04 0.12 0.003 0.01 0.002 0.01
Amitriptyline 0.16 0.55 0.33 1.09 0.30 1.02 0.02 0.07 0.01 0.03
Nortriptyline 0.33 1.11 0.63 2.11 0.61 2.03 0.03 0.10 0.02 0.06
Norsertraline – – – – 1.07 3.58 0.09 0.28 – –
Anti-epileptic Carbamazepine 0.08 0.38 0.19 0.93 0.27 1.37 0.01 0.03 0.10 0.48
Carbamazepine-10,11-epoxide 0.16 0.53 0.55 1.82 0.53 1.76 – – – –
10,11-Dihydro-10-
hydroxycarbamazepine
0.34 3.37 0.84 8.41 0.99 9.94 0.02 0.25 0.43 4.35
Calcium channel
blocker
Diltiazem 0.11 1.11 0.32 3.23 0.27 2.68 – – – –
Verapamil 0.01 0.02 0.01 0.04 0.01 0.03 0.001 0.002 0.0004 0.001
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MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
Hypnotic Temazepam 0.08 0.38 0.14 0.69 0.18 0.92 0.01 0.04 0.16 0.82
Oxazepam 0.11 0.36 0.22 0.72 0.20 0.66 – – 0.01 0.03
Diazepam 0.02 0.06 0.04 0.13 0.04 0.12 0.002 0.01 0.002 0.01
Antipsychotic Quetiapine 0.10 0.48 0.21 1.07 0.26 1.32 0.004 0.02 0.05 0.26
Risperidone 0.01 0.02 0.02 0.06 0.02 0.06 0.001 0.004 0.002 0.01
Dementia Donepezil 0.55 1.83 1.54 5.12 1.48 4.93 0.09 0.30 0.09 0.29
Memantine 0.04 0.14 0.11 0.36 0.12 0.39 0.02 0.07 0.01 0.04
Human indicators Creatinine 511* 1686* 771* 2544* 945* 3118* – – – –
Nicotine 3.34 11.0 5.44 18.0 508* 2296* 0.16 – 0.66 2.19
Caffeine 0.37 1.83 1.11 5.57 121* 581* – – – –
Cotinine 0.07 0.35 0.21 1.06 0.27 1.34 0.005 0.02 0.24 1.22
1,7-Dimethylxanthine 3.19 10.5 11.4 37.6 560* 2165* – – – –
Analgesics and
metabolites
Morphine 2.65 8.75 6.34 20.9 8.85 29.2 0.11 0.37 1.92 6.33
Dihydromorphine 0.11 0.55 0.32 1.59 0.05 2.51 0.01 0.04 0.09 0.45
Normorphine 3.54 11.7 7.84 25.9 9.99 33.0 0.12 0.39 1.74 5.75
Methadone 0.11 0.54 0.21 1.04 0.20 1.01 0.01 0.03 0.03 0.17
EDDP 0.21 1.05 0.29 1.47 0.23 1.13 0.01 0.03 0.04 0.20
Codeine 0.74 3.71 1.46 7.31 2.56 12.8 0.04 0.21 0.33 1.66
Norcodeine 2.88 9.52 8.32 27.4 8.53 28.2 0.19 0.64 1.26 4.17
Dihydrocodeine 0.23 0.75 0.55 1.83 0.88 2.89 0.02 0.05 0.11 0.36
Tramadol 0.08 8.20 0.21 21.3 0.30 30.0 0.01 0.62 0.03 3.26
N-Desmethyltramadol 0.12 5.92 0.30 15.0 0.56 27.9 0.01 0.30 0.04 2.02
O-Desmethyltramadol 0.09 8.53 0.28 27.8 0.31 31.4 – – – –
Stimulants and metabolites Amphetamine 0.68 2.23 1.11 3.65 1.23 4.07 0.01 0.05 0.09 0.29
Methamphetamine 0.32 1.05 0.71 2.35 0.95 3.13 0.01 0.04 0.09 0.30
MDMA 0.10 0.50 0.27 1.35 0.34 1.70 0.01 0.03 0.04 0.18
MDA 0.53 1.74 1.00 3.30 0.99 3.26 – – – –
Cocaine 0.07 0.35 0.22 1.11 0.46 2.31 0.01 0.03 0.03 0.15
Benzoylecgonine 0.07 0.34 0.18 0.91 0.21 1.07 0.005 0.02 0.03 0.14
Anhydroecgonine
methyl ester
0.93 4.67 1.99 9.96 2.95 14.8 – – – –
Cocaethylene 0.07 0.35 0.21 1.04 1.31 6.54 0.01 0.03 0.03 0.17
Mephedrone 0.22 1.09 0.44 2.19 0.55 2.75 0.01 0.04 0.06 0.31
MDPV 0.04 0.22 0.12 0.59 0.48 2.41 0.01 0.03 0.04 0.20
Opioid and
metabolite
Heroin 0.92 4.62 3.44 17.2 4.18 20.9 0.05 0.25 0.56 2.79




Thiamethoxam 0.13 0.42 0.44 1.46 0.53 1.76 0.01 0.03 0.01 0.02
Imidacloprid 0.04 0.15 0.10 0.33 0.10 0.33 0.01 0.02 – –
Clothianidin 0.06 0.19 0.14 0.47 0.15 0.50 0.004 0.01 – –
Metazachlor 0.02 0.06 0.04 0.14 0.04 0.13 0.002 0.01 0.002 0.01
Terbuthylazine 0.03 0.11 0.07 0.22 0.07 0.23 0.01 0.02 0.01 0.02
Methiocarb 0.13 0.43 0.27 0.91 0.26 0.86 0.01 0.04 0.01 0.04
Dichlofluanid – – – – 25.2 83.8 – – – –
Flufenacet 0.01 0.04 0.02 0.07 0.02 0.07 0.002 0.01 0.002 0.01
Oxadiazon 0.15 0.49 0.26 0.85 0.30 0.98 0.08 0.26 0.05 0.16
Chlorpyrifos 12.9 42.9 8.54 28.5 – – – – 0.33 1.09
Triallate 0.11 0.37 0.20 0.68 0.09 0.31 – – – –
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influent, as this is generally used for plant protection, particularly
against slugs. It is thought to be an unlikely compound to make
its way into influent and thought to enter surfacewaters via direct
application to the environment. Its presence in the sewage treat-
ment works, although in a low concentration, is notable as it may
indicate incorrect disposal, although a higher concentration
would be expected from this. It was recently banned for use as
a molluscicide in 2014, the grace period of which ended the
month before these samples were collected; however, it could
still be used as an insect repellent and seed treatment [46]. Other
pesticides found in influent at this site include imidacloprid and
flufenacet, which are more widely used for vegetable and fruit
crops and may be due to rinsing of food prior to consumption.
However, this needs further detailed investigation.
Of further interest is the presence of veterinary pharmaceuti-
cals in wastewater, and the presence of these can be justified by
considering the number of household pets and the possible dis-
posal route of pet waste down the lavatory. However, it is inter-
esting to note that sulfapyridine (1339.5 ± 330.3 ng L−1) and
ceftiofur (451.8 ± 129.2 ng L−1) are usually reserved for the use
with individual pigs and cows. These levels suggest potential
herd applications, incorrect disposal or unknown contribution
of livestock wastewater to this WwTW. Further investigation is
needed to determine the source and persistence of these levels.
For the solid portion of influent (SPM), 64% of the 98
analytes quantifiable with this method were found. Only a
small fraction of the total concentration can be found in the
SPM, as most CECs, particularly pharmaceuticals, prefer to
partition to the aqueous phase. For example, only a fraction of
the total concentration (6.4%) of bisphenol A (3.64 log Kow)
appears in SPM. However, in this case, the concentrations are
so high in influent that this results in bisphenol A contributing
a large portion of the total measurable concentration of CECs.
Concentrations range from an average concentration of
0.1 ng L−1 to 1383 ng L−1 in SPM (converted to ng L−1 for
simple comparison to influent concentrations). Ketoconazole
prefers to partition to the solid phase with 31% higher average
concentration present in SPM. This is not surprising when
considering its logKow of 4.45. The antidepressants fluoxetine
(4.65 log Kow) and amitriptyline (4.95 log Kow) partition
partially with SPM concentrations at 82% and 73% to that in
influent. The results for fluoxetine are in line with the results
published by Baker and Kasprzyk-Hordern [47]. However,
sorption of amitriptyline is far higher in this study. This to
be expected, as influent is highly variable, and many factors
can affect sorption to solids. Therefore, it is important to ana-
lyse both the liquid and solid compartments of this matrix.
There are fewer CECs in effluent than in influent. Of the
137 analytes quantifiable in effluent, 62% were found at the
WwTW. Generally, these results show lower concentrations
after treatment. However, imatinib, O-desmethyltramadol,
carbamazepine and its epoxide metabolite and venlafaxine
and its metabolite increase in effluent. For metabolites, this
may be due to degradation/metabolism of the parent com-
pound during treatment. For the parent compounds, this may
be due to the undetected presence of conjugatedmetabolites in
influent transforming back to the parent compound. This phe-
nomenon requires more detailed investigation. Comparison of
the influent and effluent concentrations can provide data on
treatment efficiencies. Trickling filters are employed at the
WwTW for the treatment of influent. The results show poor
removal of imidacloprid, tramadol, N-desmethyltramadol,
bicalutamide, ranitidine, cetirizine and fexofenadine.
Acetaminophen, on the other hand, shows high removal of
99%, similar to what is often seen in the literature for conven-
tional activated sludge treatment [11, 48]. Caffeine, its metab-
olite 1,7-dimethylxanthine and metformin are highly removed
but still at high concentrations of 2.9 ± 0.4 μg L−1, 8.4 ±
1.1 μg L−1 and 14.1 ± 0.9 μg L−1, respectively.
In the surface waters downstream of the WwTW, 51% of the
138 analytes that can be quantified are in this matrix. Of partic-
ular noteworthiness is the antidiabetic metformin, which is found
at levels > 3000 ngL−1.Metformin has very high usage, and after
administration, 100% of the dose is excreted unchanged [49].
Caldwell et al. [50] calculated the PNEC of metformin to be
1 mg L−1, based on critical evaluation of previously published
work. This suggests that despite the high environmental levels,
metformin is currently of low risk to this catchment. Within the
literature, many compounds can be found to have different
PNECs due to a lack of consistency in (a) assessment factors
Table 2 (continued)










MDL MQL MDL MQL MDL MQL MDL MQL MDL MQL
Veterinary
pharmaceuticals
Tylosin 1.28 6.39 2.23 11.1 3.27 16.3 – – – –
Sulfapyridine 0.04 0.14 0.11 0.37 0.10 0.33 – – – –
Sarafloxacin 0.83 2.78 2.66 8.86 2.01 6.72 – – – –
Ceftiofur 2.17 7.23 1.32 4.41 1.02 3.39 – – – –
Diazinon 0.03 0.11 0.07 0.23 0.06 0.21 0.00 0.01 0.003 0.01
*Calculated for direct injection
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used, (b) limited sources or databases used in studying
ecotoxicity data and (c) varying criteria in accepting ecotoxicity
study results. This has highlighted the need to harmonise these
methods to ensure PNECs are calculated consistently, to provide
comparable comparisons between studies and to be clearer of the
risks CECs pose to the environment.
Regarding digested solids, the concentrations are in ng g−1
of solid material, which cannot be directly compared to the
concentrations of the other matrices, as it is a combination of
sludge from various parts of the wastewater treatment process.
However, it is an important consideration as a source of CECs
in the environment, due to subsequent direct application to the
land in agricultural practices. Of the 96 analytes that can be
quantified with this method, 55% were found at this site.
Antidepressants are high in concentration, with average con-
centrations of five of the analytes between 126.3 and
782.9 ng g−1. Of the more industrial CECs, methylparaben
and bisphenol A are present in solids at high levels. In particu-
lar, bisphenol A has been quantified at levels exceeding
4000 ng g−1 at this site. Gemfibrozil, an antihyperlipidaemic,
although not found in other matrices at this site, was quantified
in digested solids at a concentration of 849.6 ± 183.8 ng g−1.
This suggests accumulation of gemfibrozil in other sections of
the WwTW that were not analysed. Due to the low MQL, the
lack of incoming concentration during the sampling period sug-
gests occasional loads high in gemfibrozil before the study.
Conclusions
This work presents a validated multi-residue method for the
analysis of 195 compounds in five matrices (3 liquid and 2
solid). These CECs cover a variety classes, both veterinary
and human pharmaceuticals, industrial chemical, personal
care products and pesticides. Application of the method to
environmental matrices has shown that the method is appro-
priate for assessing treatment efficiency, partitioning to solids,
and environmental concentrations. Discussion of the results
has identified several key areas regarding environmental risk
assessment, e.g. PNECs that need to be addressed; however,
that is outside the scope of this paper. The achieved MDL and
MQL concentrations appear low enough to be used to assess
the environmental risk of these CECs. The results show a need
for analysing both the liquid and solid phases within a
WwTW; however, it also indicates a need to monitor all out-
going treated waste materials, e.g. effluent and digested
sludge. This was due to the appearance of gemfibrozil, which
was not present at quantifiable levels in any other matrix at
this site. Overall, this method is suitable to be used in
catchment-based exposure-driven studies to further increase
knowledge of the contribution of CECs by WwTWs to the
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Table S3 MS/MS detection parameters for internal standards sorted by analogue analyte class, includes internal 
standards from ESI –ve and ESI +ve methods 
 
ISTD Method Precursor 
(m/z) 
Product 





Metronidazole-d4 A-ESI+ 175.9 127.9 26 15 
Gabapentin-d4 A-ESI+ 176 158.1 33 16 
Methiocarb-d3 A-ESI+ 228.9 168.9 25 9 
Nortriptyline-d3 A-ESI+ 267.1 191 40 20 
Amitriptyline-d3 A-ESI+ 281.5 90.9 40 25 
Metazachlor-d6 A-ESI+ 284 215.9 21 10 
Diazepam-d5 A-ESI+ 290.1 153.9 56 28 
Oxazepam-d5 A-ESI+ 292.0 245.9 38 22 
Norsertraline-d4 A-ESI+ 296 278.8 39 8 
Ciprofloxacin-d8 A-ESI+ 340.1 321.9 55 21 
Cefalexin-d5 A-ESI+ 353.2 194.5 43 10 
Ofloxacin-d3 A-ESI+ 364.8 260.8 47 28 
Verapamil-d7 A-ESI+ 462.1 165 56 31 
Sildenafil-d8 A-ESI+ 482.9 108.0 60 31 
Erythromycin-
13C,D3 
A-ESI+ 738.5 162 46 33 
Metformin-d6 B-ESI+ 136.1 77.0 30 19 
Morphine-d3 B-ESI+ 289.1 152.1 53 56 
Atenolol-d5 B-ESI+ 274.3 145.1 44 30 
Acetaminophen-d4 B-ESI+ 156.0 114.0 26 16 
Codeine-d6 B-ESI+ 306.2 218.1 52 28 
Cotinine-d3 B-ESI+ 180.1 80.0 44 24 
1S,2R-(+) 
Ephedrine-d3 
B-ESI+ 169.2 151.0 23 18 
Amphetamine-d5 B-ESI+ 141.1 92.8 20 14 
Methamphetamine-
d5 
B-ESI+ 155.1 91.8 28 18 
MDA-d5 B-ESI+ 185.1 168.1 21 11 
MDMA-d5 B-ESI+ 199.1 165.1 26 13 
Benzoylecgonine-d8 B-ESI+ 298.2 171.1 38 19 
Mephedrone-d3 B-ESI+ 181.1 148.0 30 22 
Ketamine-d4 B-ESI+ 242.1 129.1 31 27 
Heroin-d9 B-ESI+ 379.2 165.8 51 50 
ISTD Method Precursor 
(m/z) 
Product 





Norketamine-d4 B-ESI+ 228.1 128.9 32 28 
Metoprolol-d7 B-ESI+ 275.4 123.1 44 20 
Cocaine-d3 B-ESI+ 307.2 185.1 40 20 
Cocaethylene-d3 B-ESI+ 321.2 199.1 40 22 
Mirtazapine-d3 B-ESI+ 269.0 194.9 35 25 
EDDP-d3 B-ESI+ 281.2 234.1 50 29 
Propranolol-d7 B-ESI+ 267.0 188.8 40 18 
Citalopram-d6 B-ESI+ 331.0 109.0 46 28 
Carbamazepine-
13C6 
B-ESI+ 243.1 200.1 40 20 
Quetiapine-d8 B-ESI+ 392.1 258.1 50 23 
Methadone-d9 B-ESI+ 319.3 268.2 31 15 
Temazepam-d5 B-ESI+ 306.7 260.1 37 21 
Fluoxetine-d5 B-ESI+ 315.3 153.2 26 8 
Sertraline-d3 B-ESI+ 309.1 159.0 23 27 
Tamoxifen-13C2-
15N 
B-ESI+ 375.1 75.0 50 25 
Methylparaben-13C C-ESI- 156.9 97.9 30 20 
Ketoprofen-d3 C-ESI- 265.0 212.0 15 7 
Bezafibrate-d6 C-ESI- 366.0 274.0 30 19 
Naproxen-d13 C-ESI- 232.0 188.0 15 8 
Bisphenol A-d16 C-ESI- 241.1 223.1 40 20 
Ibuprofen-d3 C-ESI- 208.0 164.0 20 6 
E2 (2, 4, 16, 16)-d4 C-ESI- 275.1 147.0 60 40 






Fig. S1 Chromatograms of all analytes in spiked influent sample from Site A using methods: A-ESI+, B-ESI+ 
and C-ESI-. The run time for C-ESI- is 22.5 minutes, which is shorter than the 34 minute run time of A-ESI+ 


















































































































































































































































































































Table S6 Adsorbance 
 
Spiked Surface 
water adsorbance to 
PPE bottle after 24h 
storage 
Recovery 24h 
storage on SPE 
cartridge 
Compound Ads (%) SD Rec (%) SD 
Benzophenone-1 - - - - 
Benzophenone-2 - - - - 
Benzophenone-3 33.7 18.7 45.3 16.0 
Benzophenone-4 - - - - 
Methylparaben - - - - 
Ethylparaben - - - - 
Propylparaben - - - - 
Butylparaben - - - - 
Bisphenol A - - - - 
E1 - - - - 
E2 - - - - 
EE2 - - - - 
Sulfasalazine - - - - 
Clarithromycin -6.4 2.1 106.8 11.8 
Trimethoprim 5.2 3.0 94.7 4.3 
Sulfamethoxazole 9.3 0.1 98.8 3.9 
Triclosan - - - - 
Amoxicillin - - - - 
Metronidazole -6.8 4.8 107.4 2.1 
Sulfadiazine 37.6 3.6 97.9 10.9 
Cefalexin  - - - - 
Ofloxacin 18.1 16.4 96.8 6.4 
Ciprofloxacin - - - - 
Tetracycline - - - - 
Danofloxacin - - - - 
Oxytetracycline - - - - 
Chloramphenicol -9.7 16.1 126.5 10.7 
Penicillin G - - - - 
Penicillin V -60.9 55.6 149.7 41.9 
Erythromycin -4.0 11.2 146.2 71.1 
Azithromycin 16.6 2.3 115.0 21.6 
Prulifloxacin - - - - 
Norfloxacin - - - - 
Griseofulvin -0.3 8.4 98.2 3.2 
Ketoconazole -10.6 2.9 104.6 13.6 
Valsartan - - - - 
Irbesartan - - - - 
Lisinopril 73.7 20.8 22.0 1.6 
Ketoprofen - - - - 
Ibuprofen - - - - 
Naproxen - - - - 





water adsorbance to 
PPE bottle after 24h 
storage 
Recovery 24h 
storage on SPE 
cartridge 
Compound Ads (%) SD Rec (%) SD 
Acetaminophen 1.4 3.1 97.3 2.7 
Bezafibrate - - - - 
Atorvastatin - - - - 
Gemfibrozil -15.5 11.2 107.0 4.2 
Candesartan Cilexetil -141.2 53.2 322.5 208.8 
Fexofenadine - - - - 
Cetirizine 1.6 0.7 89.8 6.1 
Sildenafil -9.8 7.6 107.1 3.9 
Metformin -62.3 5.1 71.5 10.4 
Gliclazide 6.3 6.6 107.3 3.3 
Sitagliptin 15.6 5.0 149.4 34.5 
Pholcodine 43.4 1.8 65.2 4.4 
Atenolol -6.8 3.8 109.6 1.5 
Metoprolol 7.8 1.0 98.8 1.3 
Propranolol -12.4 7.3 108.2 16.1 
Bisoprolol 6.0 10.1 118.5 22.0 
Ranitidine 30.7 5.7 118.8 5.8 
Cimetidine 52.5 0.7 99.2 2.4 
Iopromide -11.2 2.5 108.1 3.1 
Buprenorphine 0.5 1.5 151.6 26.9 
Ephedrine/pseudoephedrine 52.9 0.8 93.5 5.1 
Norephedrine 18.0 1.8 129.5 23.5 
Azathioprine 5.6 3.3 95.6 1.3 
Methotrexate 30.2 0.8 57.0 7.2 
Ifosfamide 5.5 0.1 99.3 0.3 
Tamoxifen 60.2 5.9 73.0 26.7 
Imatinib 11.7 2.2 101.9 17.7 
Capecitabine -1.1 2.2 94.2 4.7 
Bicalutamide -19.7 14.4 95.3 14.0 
Ketamine -2.7 0.7 110.2 2.5 
Norketamine 5.4 1.3 98.4 1.0 
Venlafaxine 3.8 1.3 101.9 2.6 
Desvenlafaxine -1.3 1.8 103.1 3.7 
Fluoxetine -22.2 21.6 121.4 32.9 
Norfluoxetine 58.4 9.2 71.3 36.6 
Sertraline 1.4 20.6 96.0 25.8 
Mirtazapine 6.0 1.6 100.4 6.6 
Citalopram 2.5 4.6 92.4 14.5 
Desmethylcitalopram -2.0 7.0 110.1 17.9 
Paroxetine 35.8 15.7 85.4 16.4 
Duloxetine - - - - 
Amitriptyline 14.0 3.1 95.8 6.2 
Nortriptyline 30.0 0.8 110.0 9.8 





water adsorbance to 
PPE bottle after 24h 
storage 
Recovery 24h 
storage on SPE 
cartridge 
Compound Ads (%) SD Rec (%) SD 
Carbamazepine 6.3 2.1 96.2 0.7 
Carbamazepine 10,11 epoxide -7.8 0.9 109.5 0.8 
10,11 dihydro 10 
hydroxycarbamazepine 17.4 0.7 82.4 0.1 
Diltiazem -2.0 3.9 91.6 17.3 
Verapamil 9.1 3.0 94.5 4.9 
Temazepam -0.5 2.2 100.8 0.7 
Oxazepam 14.9 0.4 89.6 0.5 
Diazepam -17.7 0.2 119.4 0.6 
Quetiapine -7.3 5.3 97.0 14.5 
Risperidone 14.8 8.3 118.5 19.6 
Donepezil 16.4 13.7 118.9 29.4 
Memantine 3.2 10.4 174.0 41.0 
Creatinine 75.4 0.7 37.8 7.3 
Nicotine -11.8 6.0 147.9 5.6 
Caffeine 4.6 0.5 96.8 1.6 
Cotinine 0.1 3.0 97.3 1.0 
1,7 dimethylxantine -4.4 3.7 99.1 6.2 
Morphine 3.3 10.1 104.7 2.7 
Dihydromorphine 24.1 2.6 90.2 0.5 
Normorphine 17.0 4.5 107.4 3.3 
Methadone 1.5 0.7 101.2 11.4 
EDDP 53.7 1.3 98.3 11.8 
Codeine 1.2 5.1 107.0 4.9 
Norcodeine 6.6 7.0 106.7 5.3 
Dihydrocodeine 14.7 0.2 95.1 0.7 
Tramadol 1.9 2.3 101.8 0.1 
N-desmethyltramadol 16.7 4.3 99.0 3.5 
O-desmethyltramadol 4.0 0.4 99.2 2.0 
Amphetamine 43.3 1.0 87.1 0.1 
Methamphetamine 3.2 0.7 118.2 1.8 
MDMA 21.0 2.5 90.2 2.8 
MDA 44.4 2.5 82.1 4.1 
Cocaine 1.4 0.1 99.7 2.0 
Benzoylecgonine 1.0 0.7 95.9 0.2 
Anhydroecgonine methylester 10.3 3.7 108.7 3.5 
Cocaethylene 6.0 2.0 94.8 2.4 
Mephedrone 33.6 4.3 90.1 7.3 
MDPV 38.9 3.4 82.8 7.0 
Heroin 17.8 0.8 87.7 4.4 
O-6-MAM 15.6 2.8 93.8 2.9 
Thiamethoxam -1.7 6.0 106.1 2.2 
Imidacloprid 1.1 1.0 95.2 2.3 





water adsorbance to 
PPE bottle after 24h 
storage 
Recovery 24h 
storage on SPE 
cartridge 
Compound Ads (%) SD Rec (%) SD 
Metazachlor 2.1 6.7 96.9 14.2 
Terbuthylazine -13.9 3.7 119.0 0.8 
Methiocarb 4.1 5.4 99.3 5.3 
Dichlofluanid - - - - 
Flufenacet -9.7 0.6 103.1 1.3 
Oxadiazon -27.6 28.9 74.1 15.8 
Chlorpyrifos -3.3 0.3 112.0 5.8 
Triallate -44.7 33.0 136.8 9.9 
Tylosin 11.4 7.5 86.0 1.4 
Sulfapyridine -2.9 3.9 103.7 1.0 
Sarafloxacin - - - - 
Ceftiofur 73.2 2.7 29.9 13.8 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S9 Solid matrix absolute and corrected recoveries 
 Absolute Corrected 
 SPM Digested Solids SPM Digested Solids 
Compound Rec (%) SD Rec (%) SD Rec (%) SD Rec (%) SD 
Benzophenone-1 41.4 8.4 8.1 2.2 120.0 9.1 69.7 58.6 
Benzophenone-2 34.3 2.8 11.1 0.8 141.3 9.7 105.5 19.0 
Benzophenone-3 - - - - - - - - 
Benzophenone-4 17.5 2.8 7.6 1.8 72.6 5.5 47.0 9.9 
Methylparaben 44.2 7.7 18.1 11.9 149.1 22.4 110.3 81.5 
Ethylparaben 40.2 7.8 19.5 0.7 109.5 26.7 118.7 13.0 
Propylparaben 49.5 4.1 16.0 0.6 200.4 14.6 153.6 30.8 
Butylparaben 36.8 2.8 11.2 0.7 247.0 10.4 179.6 14.3 
Bisphenol A 35.7 10.0 11.9 - 58.8 12.0 95.7 - 
E1 16.2 1.9 5.9 2.1 115.3 8.5 106.6 28.0 
E2 14.0 1.5 6.4 0.8 109.4 12.6 113.6 9.9 
EE2 - - - - - - - - 
Sulfasalazine - - - - - - - - 
Clarithromycin - - - - - - - - 
Azithromycin 7.6 6.0 14.0 12.0 22.4 4.8 60.5 17.7 
Trimethoprim 69.3 17.2 44.9 2.5 146.0 30.9 138.5 6.6 
Sulfamethoxazole 36.1 2.9 24.4 2.4 62.7 2.3 74.4 5.8 
Triclosan - - - - - - - - 
Amoxicillin 22.9 18.7 26.3 25.2 - - - - 
Metronidazole 8.0 1.6 5.6 0.3 121.2 18.4 103.1 6.9 
Sulfadiazine 9.9 1.7 - - 151.6 19.3 166.0 36.4 
Cefalexin  - - - - - - - - 
Ofloxacin 6.3 3.9 - - - - - - 
Ciprofloxacin 9.3 3.7 0.9 1.0 - - - - 
Tetracycline - - 12.5   - - - - 
Danofloxacin - - 0.3 0.4 - - 5.6 0.7 
Oxytetracycline - - - - - - - - 
Chloramphenicol 26.3 2.3 17.2 3.5 125.3 9.2 179.5 19.5 
Penicillin G - - - - - - - - 
Penicillin V 1.9 0.7 29.0 18.4 8.7 2.3 - - 
Erythromycin - - - - - - - - 
Prulifloxacin -0.8   -41.8 22.9 156.0   - - 
Norfloxacin - - - - - - - - 
Griseofulvin 17.8 3.1 6.6 1.2 82.0 10.1 60.6 9.5 
Ketoconazole 8.5 1.7 -3.2 18.3 13.3 1.8 100.6 17.8 
Valsartan - - - - - - - - 
Irbesartan - - - - - - - - 
Lisinopril 67.6 6.7 37.7 2.9 109.1 10.9 127.8 14.5 
Ketoprofen 28.9 1.0 23.1 3.8 98.2 5.0 119.4 8.6 
Ibuprofen 42.3 13.9 14.9 4.0 101.0 7.8 105.5 9.6 
Naproxen 44.1 9.9 16.4 2.3 96.5 14.6 107.9 9.6 
Diclofenac 41.9 12.3 4.2 1.7 88.3 13.9 40.8 14.6 
Acetaminophen 14.8 3.6 3.9 0.5 129.8 25.8 57.7 10.8 
31 
 
 Absolute Corrected 
 SPM Digested Solids SPM Digested Solids 
Compound Rec (%) SD Rec (%) SD Rec (%) SD Rec (%) SD 
Bezafibrate 32.3 2.5 16.4 2.2 98.0 8.7 112.5 5.5 
Atorvastatin - - - - - - - - 
Gemfibrozil 7.5 3.9 2.9 0.3   - 26.3 1.6 
Candesartan Cilexetil - - - - - - - - 
Fexofenadine - - - - - - - - 
Cetirizine - - - - - - - - 
Sildenafil 35.6 2.2 26.2 1.5 110.9 6.4 116.7 4.9 
Metformin - - - - - - - - 
Gliclazide - - - - - - - - 
Sitagliptin 42.0 3.7 30.0 3.8 79.4 7.9 99.2 8.1 
Pholcodine 29.7 2.6 22.8 2.7 62.0 4.2 87.8 11.0 
Atenolol 52.1 4.6 30.8 2.7 105.2 9.4 121.0 10.8 
Metoprolol 57.7 2.1 36.6 1.6 95.1 3.9 99.7 4.9 
Propranolol 42.7 5.6 20.9 4.8 103.3 8.4 91.5 14.0 
Bisoprolol 38.1 5.9 26.6 3.8 125.8 9.9 126.1 8.6 
Ranitidine 61.7 8.3 21.5 1.9 117.8 17.8 82.1 3.6 
Cimetidine - - - - - - - - 
Iopromide - - - - - - - - 
Buprenorphine 18.1 3.6 12.4 2.0 59.9 9.4 88.0 8.5 
Ephedrine/pseudoephedrin
e 40.0 3.1 28.2 5.2 72.9 2.8 97.9 21.0 
Norephedrine 37.2 3.9 27.0 5.6 64.0 5.1 92.6 18.9 
Azathioprine - - - - - - - - 
Methotrexate 48.2 1.5 16.9 2.6 87.1 2.2 59.3 8.7 
Ifosfamide - - - - - - - - 
Tamoxifen 15.9 9.5 0.3 0.0 118.7 49.7 112.7 7.0 
Imatinib 9.0 2.1 10.5 2.4 39.9 8.4 65.3 10.8 
Capecitabine 4.8 2.5 5.0 1.0 22.1 0.5 53.4 5.8 
Bicalutamide 23.0 3.5 21.8 4.0 87.0 8.3 176.0 30.6 
Ketamine 48.5 3.3 29.0 0.9 101.7 4.3 105.3 4.3 
Norketamine 41.8 5.4 30.3 1.6 96.3 3.6 109.7 4.3 
Venlafaxine 40.7 10.1 11.3 22.5 70.3 20.8 61.9 6.4 
Desmethylvenlafaxine 58.2 5.2 33.9 3.8 104.3 5.6 96.9 10.3 
Fluoxetine 28.2 1.6 9.4 2.7 104.1 0.9 121.2 48.4 
Norfluoxetine 34.7 6.0 7.4 0.9 120.3 18.5 95.1 37.5 
Sertraline 72.1 98.5 5.8 6.2 - - 101.9 14.8 
Mirtazapine 33.0 2.0 18.5 2.3 89.2 4.6 98.2 9.9 
Citalopram 46.4 2.5 30.4 5.1 105.3 17.7 112.7 37.3 
Desmethylcitalopram 41.5 3.0 20.8 3.0 96.4 10.6 82.2 18.8 
Paroxetine 18.3 2.5 15.8 3.4 83.5 6.1 103.0 15.6 
Duloxetine 10.2 1.8 9.2 2.1 48.3 6.8 61.3 9.3 
Amitriptyline 27.9 3.5 8.9 9.1 72.0 9.2 175.2 39.5 
Nortriptyline 27.3 1.7 16.5 3.7 104.8 4.0 194.4 1.8 
Norsertraline 22.0 32.0 19.2 12.2 39.7 2.7     
Carbamazepine 30.7 1.9 10.8 0.9 98.7 3.3 94.5 13.9 
32 
 
 Absolute Corrected 
 SPM Digested Solids SPM Digested Solids 
Compound Rec (%) SD Rec (%) SD Rec (%) SD Rec (%) SD 
Carbamazepine 10,11-
epoxide - - - - - - - - 
10,11-Dihydro -10-
hydroxycarbamazepine 31.6 3.5 11.5 0.6 101.6 8.3 100.1 2.8 
Diltiazem - - - - - - - - 
Verapamil 46.3 5.9 34.3 2.1 102.5 10.6 130.8 6.7 
Temazepam 9.5 2.2 6.1 1.6 58.5 5.5 92.3 6.6 
Oxazepam 0.5 N/A 1.4 0.7 115.0   115.1 15.5 
Diazepam 24.4 4.0 17.3 2.4 82.2 6.8 99.3 1.7 
Quetiapine 51.6 3.5 19.1 3.1 113.9 5.3 81.9 9.0 
Risperidone 36.3 7.0 15.7 4.2 75.8 6.6 57.4 12.8 
Donepezil 41.6 8.7 26.8 4.2 97.2 11.6 98.3 11.0 
Memantine 20.0 1.6 19.6 3.7 36.6 9.2 71.4 10.6 
Creatinine - - - - - - - - 
Nicotine 50.1 7.8 45.6 4.0 92.7 12.5 165.4 24.4 
Caffeine - - - - - - - - 
Cotinine 10.9 1.5 4.1 1.7 102.7 2.8 112.1 11.6 
1,7-dimethylxanthine - - - - - - - - 
Morphine 27.1 3.8 15.8 6.3 137.0 28.6 114.0 30.9 
Dihydromorphine 13.2 1.9 11.0 1.2 64.6 3.9 74.3 3.4 
Normorphine 25.1 4.3 17.4 4.0 127.2 14.6 109.9 17.2 
Methadone 46.3 2.4 29.2 0.7 95.5 3.8 102.8 3.2 
EDDP 35.6 3.4 25.5 2.8 98.2 5.7 103.8 9.3 
Codeine 58.7 8.3 30.2 1.9 116.5 25.7 105.3 19.0 
Norcodeine 39.1 5.3 24.0 1.9 77.9 5.6 87.8 10.8 
Dihydrocodeine 44.5 4.4 27.8 2.1 91.1 5.6 101.0 10.4 
Tramadol 47.1 3.0 30.7 2.1 80.8 3.6 87.7 6.1 
N-desmethyltramadol 44.1 4.5 24.7 1.5 84.3 4.1 83.4 10.7 
O-desmethyltramadol - - - - - - - - 
Amphetamine 60.8 3.7 34.1 2.5 110.7 4.2 118.3 8.7 
Methamphetamine 53.4 2.1 33.8 1.8 113.2 5.0 104.4 2.1 
MDMA 45.0 2.5 28.1 1.3 96.0 2.6 105.6 1.9 
MDA - - - - - - - - 
Cocaine 52.0 2.3 32.8 1.6 99.2 3.7 104.7 2.9 
Benzoylecgonine 54.4 4.4 35.7 1.9 100.4 3.9 117.3 7.3 
Anhydroecgoninemethylest
er - - - - - - - - 
Cocaethylene 48.5 2.9 30.0 1.3 99.8 3.8 98.9 6.5 
Mephedrone 23.3 3.2 15.9 1.5 61.9 3.3 99.4 4.1 
MDPV 44.0 4.6 24.6 2.7 88.3 5.2 79.7 8.3 
Heroin 27.7 1.8 17.9 2.2 98.7 4.9 91.7 6.5 
6-acetylmorphine - - - - - - - - 
Thiamethoxam 20.1 4.8 15.1 3.5 95.3 20.6 140.7 26.1 
Imidacloprid 29.0 7.3 24.2 2.9 103.2 21.4 - - 
Clothianidin 32.6 6.8 29.9 3.0 159.3 27.1 - - 
Metazachlor 26.0 3.4 8.9 1.8 92.7 5.5 96.1 8.0 
33 
 
 Absolute Corrected 
 SPM Digested Solids SPM Digested Solids 
Compound Rec (%) SD Rec (%) SD Rec (%) SD Rec (%) SD 
Terbuthylazine 13.3 1.6 8.4 1.9 45.3 7.6 47.4 4.9 
Methiocarb 22.3 1.6 12.6 1.1 104.3 5.5 117.5 3.7 
Dichlofluanid - - 0.0 0.2 - - - - 
Flufenacet 14.7 2.0 5.6 1.0 45.9 4.6 57.9 10.5 
Oxadiazon 3.0 1.1 2.5 0.6 14.8 1.9 25.0 4.0 
Chlorpyrifos 4.6 2.4 7.9 1.9 - - 86.1 20.0 
Triallate 2.3 0.9 4.1 1.7 - - - - 
Tylosin - - - - - - - - 
Sulfapyridine 26.5 5.1 23.5 4.5 - - - - 
Sarafloxacin 6.3 2.8 - - - - - - 
Ceftiofur - - - - - - - - 





Fig. S2 Absolute recoveries for all matrices, error bars indicate the range of standard deviation 
35 
 
Table S10 Matrix suppression 
 Surface water Effluent Influent 
Compound (%) SD (%) SD (%) SD 
Benzophenone-1 0.6 2 2 4.5 30.6 0.1 
Benzophenone-2 43.8 1.1 49.2 1.9 55.5 1 
Benzophenone-3 -5.1 1 7.7 3.3 20.7 1.1 
Benzophenone-4 -1.2 9.4 23 6.8 42.5 1.7 
Methylparaben 41.9 3.6 49.1 1.5 60.2 1.4 
Ethylparaben 27.8 3.4 29.8 0.6 37 2.9 
Propylparaben 21.7 4.3 21.6 2.1 37.3 4.2 
Butylparaben 8 1.9 11 1.4 35.9 2.4 
Bisphenol A 15 0.2 12.4 2.6 29.4 2.9 
E1 4.5 4.3 5 1.1 28.6 1.4 
E2 8.3 8.1 8 5.9 31.8 0.9 
EE2 -6.1 1.7 -24.4 3.9 13.2 4.8 
Sulfasalazine -105.8 9.9 -81.7 3.1 -53.4 5.1 
Clarithromycin 52 1.6 54.1 0.5 54 1.2 
Azithromycin 72.7 0.6 73.9 1.9 68.8 3.9 
Trimethoprim 38.2 0.8 51 2.7 49.1 4.5 
Sulfamethoxazole 28.4 0.4 38.1 1.5 47.6 0.8 
Triclosan -62.3 0.3 -100.9 3.1 -99 4.8 
Amoxicillin 99.8 0.7 93.9 0.7 99.0 0.7 
Metronidazole 24.5 1.3 47.4 5.9 51.3 1.5 
Sulfadiazine 37.1 1.1 64.6 1.8 71.1 1.1 
Cefalexin  37.7 4.8 28.4 12.9 31.5 5.6 
Ofloxacin 29.3 9.9 40.2 3.3 48.4 3.3 
Ciprofloxacin 67.8 5.4 69.5 1.0 74.1 3.5 
Tetracycline 6.5 1.3 27.3 0.9 36.7 9.0 
Danofloxacin 70.2 5.7 73.7 2.7 81.3 3.8 
Oxytetracycline 13.9 0.8 29.3 3.4 22.5 22.6 
Chloramphenicol 33.4 2.4 39.3 1.2 45.7 3.3 
Penicillin G 101.1 0.1 100.5 0.2 96.7 0.8 
Penicillin V -15.4 10.8 -13.1 33.7 -2.5 6.9 
Erythromycin 36.5 11.2 -195.6 14.7 57.8 6.8 
Prulifloxacin 107.9 1.9 87.4 18.7 44.9 26.5 
Norfloxacin 52.7 3.9 62.2 3.1 61.5 19.3 
Griseofulvin 4.3 0.5 9.9 2.0 17.3 4.4 
Ketoconazole 90.4 4.2 44.6 0.1 38.0 3.0 
Valsartan -139.2 2.6 -105.4 5.9 -77.4 5.7 
Irbesartan -23.8 1.2 -25.3 1.3 -14.3 0.2 
Lisinopril -12.3 2.5 8.6 0.5 23.1 0 
Ketoprofen 8.5 0.2 9.9 3.2 36.3 1.5 
Ibuprofen -13.6 4.4 -24.3 9.9 -15.6 5 
Naproxen -13.2 1.6 -18.7 0.7 29.8 34.1 
Diclofenac -127.3 0.8 -141.7 5.7 -104.5 2.2 
Acetaminophen 27.8 1.9 50.6 0.6 22.2 19 
Bezafibrate -24.5 10.8 -19.6 3.7 0.7 0.5 
36 
 
 Surface water Effluent Influent 
Compound (%) SD (%) SD (%) SD 
Atorvastatin -155.7 2.9 -160.3 1.4 -152.8 14.5 
Gemfibrozil -70.3 20.5 -64.4 1.9 29.5 1.0 
Candesartan Cilexetil 100.0 23.2 -108.3 37.4 -78.1 47.6 
Fexofenadine 10.3 1.4 11.2 1.2 27.1 1.9 
Cetirizine 16.9 3 18 0.1 30.5 0.4 
Sildenafil 67.2 1.6 32.4 4.7 47.3 1.9 
Metformin 44.8 1 47 1.2 63.3 0.6 
Gliclazide 19 4.6 23.6 1.1 38.2 1.3 
Sitagliptin 23.8 0.0 30.2 0.5 38.4 1.1 
Pholcodine 11.4 2.3 45.5 0.6 90 1.4 
Atenolol 22.3 1.1 48 0.7 59.7 1.6 
Metoprolol 27.6 0.5 49.5 0.1 65.7 0.1 
Propranolol 31.2 3.7 59 1.4 56.7 0.6 
Bisoprolol 10.5 0.0 37.8 4.0 32.2 1.2 
Ranitidine 18.2 4 35 0.8 56.8 1.1 
Cimetidine 23.4 4.7 48.4 0.8 61.9 1.6 
Iopromide 11.8 2.7 26.1 3.5 39.1 0 
Buprenorphine 52.0 2.5 34.1 3.4 45.7 4.3 
Ephedrine/pseudoephedrin
e 36.5 1.6 59.8 0.1 67.7 0.1 
Norephedrine 18.2 2.6 38.4 1.2 41.3 1 
Azathioprine 32.8 0.9 45 3.1 51.1 0.9 
Methotrexate 43.2 1.8 52.3 0.2 51.1 1.1 
Ifosfamide 26.1 1 46.7 0.7 55.9 0.8 
Tamoxifen 93.2 1.3 14.6 5.3 30.3 3.2 
Imatinib 93.3 1.1 86.4 1.5 88.1 0.1 
Capecitabine 3.4 4.0 15.3 1.2 23.8 0.7 
Bicalutamide 8.8 10.2 -22.8 1.8 -16.3 1.9 
Ketamine 25.8 0.2 42.7 0.7 51.5 0.4 
Norketamine 21.6 1.8 34.6 0.9 45.4 0.6 
Venlafaxine 27.5 2.7 56.5 1 71.5 0.2 
Desmethylvenlafaxine 29.9 0.6 59.1 0.6 65.1 4.7 
Fluoxetine 75.1 4.7 84.9 0.7 53.9 1.3 
Norfluoxetine 79.5 3.4 86.6 0.3 54.8 0.4 
Sertraline 88.1 3 88.4 0.5 57.1 0.1 
Mirtazapine 26 1.1 50.2 0.7 65.2 0.2 
Citalopram 52 2.8 70.1 0.4 63.7 0.8 
Desmethylcitalopram 40.6 3.1 65.6 0.1 54.5 0.7 
Paroxetine 93.7 0.2 86.7 0.5 70.5 1.6 
Duloxetine 90.5 0.7 83.4 0.2 60.2 3.9 
Amitriptyline 78.9 1.4 71.2 0.0 61.4 1.5 
Nortriptyline 84.1 1.4 77.3 1.6 62.5 2.8 
Norsertraline 98.5 0.3 84.2 1.8 52.9 1.5 
Carbamazepine 61.4 2.5 46.6 0.5 61.4 0.4 
Carbamazepine 10,11-
epoxide 18.3 1.7 32.2 0.5 41.3 1.8 
37 
 
 Surface water Effluent Influent 
Compound (%) SD (%) SD (%) SD 
10,11-Dihydro -10-
hydroxycarbamazepine 20.3 1.6 33.2 0.2 37.3 0.2 
Diltiazem 37.9 4.3 53.6 0.1 61.4 3.6 
Verapamil 65.7 1.3 51.9 2.1 57.3 4.6 
Temazepam 14.4 0.5 22.3 2 36 0.3 
Oxazepam 7.2 0.8 9.6 1.5 21.8 3.0 
Diazepam 14.2 1.4 20.2 2.7 25.0 3.0 
Quetiapine 35 3.7 50.9 0.8 51.7 0.9 
Risperidone 54.7 0.1 58.1 0.1 64.3 1.4 
Donepezil 60.3 5.4 53.5 1.4 62.6 1.5 
Memantine 38.1 3.1 51.3 2.4 60.8 1.3 
Creatinine 69 0.4 75.2 0.1 77.2 0.6 
Nicotine 1.2 3.2 5 2.2 47 1.6 
Caffeine 22.2 3.2 53.4 8.5 17.1 34.5 
Cotinine 33 2.1 55.6 1.4 67.3 0.9 
1,7-dimethylxanthine 28.1 0.2 44.9 1.4 10.7 18.1 
Morphine 30.1 3.8 47.3 2.3 69 3.3 
Dihydromorphine 32.9 1.2 49.9 1.3 67.5 0.1 
Normorphine 27.7 7.6 46.8 4.3 60.3 0.7 
Methadone 32 3.8 48.4 0.8 45.2 0.3 
EDDP 23.4 1.7 45.1 0.2 55.4 1 
Codeine 25.9 3.9 53.7 0.5 59.8 1.3 
Norcodeine 33.1 1.8 49.1 2.4 53.5 1.3 
Dihydrocodeine 21.7 2.8 49.7 0.8 58 2.1 
Tramadol 31.8 3.6 54.5 2.2 65.1 0 
N-desmethyltramadol 30.2 0.3 55.6 0.5 80.4 0.2 
O-desmethyltramadol 34.6 0.2 59.2 1.1 62.5 0.6 
Amphetamine 23.6 1.6 36.5 1.2 50.2 0.4 
Methamphetamine 23 1.9 44.1 1.6 67 0.2 
MDMA 36.3 0.8 58.8 0 69.2 3.1 
MDA 29.7 1 44.9 0.7 50.5 1.2 
Cocaine 32.7 1.1 49.8 0.2 73.4 0.4 
Benzoylecgonine 21.9 5.2 52 0.6 61.6 0.5 
Anhydroecgoninemethyles
ter 12.5 0.3 28 1.6 48.4 0.8 
Cocaethylene 31.6 1.4 51.8 1 64.3 0.2 
Mephedrone 24.6 2.8 44.6 0.3 64.6 0.7 
MDPV 22.7 1.1 42.1 0.2 85.6 0.7 
Heroin 25 1.6 45.4 0.4 61.4 2.2 
6-acetylmorphine 46 2.1 65.1 1.8 66.9 1.7 
Thiamethoxam 37.4 2.3 70.7 0.0 75.0 0.0 
Imidacloprid 2.3 11.6 33.7 13.0 37.2 8.3 
Clothianidin 11.7 1.7 28.7 7.9 25.1 1.6 
Metazachlor 14.8 0.8 33.9 1.7 35.4 0.1 
Terbuthylazine 36.5 3.4 31.2 2.0 43.0 0.6 
Methiocarb 25.4 5.6 25.2 2.0 27.7 1.7 
38 
 
 Surface water Effluent Influent 
Compound (%) SD (%) SD (%) SD 
Dichlofluanid 59.7 0.7 94.0 6.3 57.8 6.4 
Flufenacet 22.1 0.4 27.3 2.0 36.3 1.1 
Oxadiazon 41.8 9.7 19.8 1.6 28.9 2.2 
Chlorpyrifos 87.5 5.8 32.8 6.7 -222.8 0.5 
Triallate 84.5 1.8 59.4 4.7 -23.1 2.6 
Tylosin 31.4 1.1 43.4 0.4 64.9 0.5 
Sulfapyridine 26.0 1.4 46.5 2.9 52.5 0.4 
Sarafloxacin 66.8 1.4 62.7 3.2 64.5 5.7 
Ceftiofur 18.5 28.7 37.0 7.4 10.0 1.8 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S15 Digested solids data (ng g-1) 
 Day 1 Day 2 Day 3 
Compound A B A B A B 
Benzophenone-1 N/A N/A N/A N/A N/A N/A 
Benzophenone-2 21.3 10.9 7.9 8.9 5.2 7.0 
Benzophenone-3 N/A N/A N/A N/A N/A N/A 
Benzophenone-4 <MQL <MQL <MQL <MQL <MQL <MQL 
Methylparaben 617.3 431.8 331.8 290.7 215.2 274.3 
Ethylparaben <MQL <MQL <MQL <MQL <MQL <MQL 
Propylparaben <MQL <MQL <MQL <MQL <MQL <MQL 
Butylparaben <MQL <MQL <MQL <MQL <MQL <MQL 
Bisphenol A 4984.4 4479.9 4220.1 4200.5 4010.5 4298.3 
E1 40.5 47.0 39.0 40.0 43.8 38.9 
E2 <MQL <MQL <MQL <MQL <MQL <MQL 
EE2 N/A N/A N/A N/A N/A N/A 
Sulfasalazine N/A N/A N/A N/A N/A N/A 
Clarithromycin N/A N/A N/A N/A N/A N/A 
Azithromycin 1.7 16.6 3.1 3.6 8.6 0.3 
Trimethoprim 14.4 15.1 8.5 7.9 10.3 10.2 
Sulfamethoxazole <MQL <MQL <MQL <MQL <MQL <MQL 
Triclosan N/A N/A N/A N/A N/A N/A 
Amoxicillin N/A N/A N/A N/A N/A N/A 
Metronidazole <MQL <MQL <MQL <MQL <MQL <MQL 
Sulfadiazine <MQL <MQL <MQL <MQL <MQL <MQL 
Cefalexin  N/A N/A N/A N/A N/A N/A 
Ofloxacin N/A N/A N/A N/A N/A N/A 
Ciprofloxacin N/A N/A N/A N/A N/A N/A 
Tetracycline N/A N/A N/A N/A N/A N/A 
Danofloxacin <MQL <MQL <MQL <MQL <MQL <MQL 
Oxytetracycline N/A N/A N/A N/A N/A N/A 
Chloramphenicol <MQL <MQL 359.4 368.8 328.7 453.6 
Penicillin G N/A N/A N/A N/A N/A N/A 
Penicillin V N/A N/A N/A N/A N/A N/A 
Erythromycin N/A N/A N/A N/A N/A N/A 
Prulifloxacin N/A N/A N/A N/A N/A N/A 
Norfloxacin N/A N/A N/A N/A N/A N/A 
Griseofulvin <MQL <MQL <MQL <MQL <MQL <MQL 
Ketoconazole 1164.2 1234.1 602.8 860.5 867.4 847.0 
Valsartan N/A N/A N/A N/A N/A N/A 
Irbesartan N/A N/A N/A N/A N/A N/A 
Lisinopril <MQL <MQL <MQL <MQL <MQL <MQL 
Ketoprofen <MQL <MQL <MQL <MQL <MQL <MQL 
Ibuprofen 298.3 266.0 178.4 230.9 213.5 203.8 
Naproxen 114.1 110.0 100.6 111.9 101.4 112.2 
Diclofenac 33.1 27.7 23.5 24.6 23.1 25.2 
Acetaminophen <MQL <MQL <MQL <MQL <MQL <MQL 
Bezafibrate 7.8 8.8 7.5 7.2 7.2 6.4 
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 Day 1 Day 2 Day 3 
Compound A B A B A B 
Atorvastatin N/A N/A N/A N/A N/A N/A 
Gemfibrozil 1115.2 866.8 814.3 1025.1 709.4 566.6 
Candesartan Cilexetil N/A N/A N/A N/A N/A N/A 
Fexofenadine N/A N/A N/A N/A N/A N/A 
Cetirizine N/A N/A N/A N/A N/A N/A 
Sildenafil 20.8 19.5 22.6 21.3 20.6 20.2 
Metformin N/A N/A N/A N/A N/A N/A 
Gliclazide N/A N/A N/A N/A N/A N/A 
Sitagliptin 29.3 26.9 30.3 29.1 25.9 24.2 
Pholcodine <MQL <MQL <MQL <MQL <MQL <MQL 
Atenolol <MQL <MQL <MQL <MQL <MQL <MQL 
Metoprolol <MQL <MQL <MQL <MQL <MQL <MQL 
Propranolol 236.3 223.6 189.7 183.4 176.0 182.0 
Bisoprolol <MQL <MQL <MQL <MQL <MQL <MQL 
Ranitidine <MQL <MQL <MQL <MQL <MQL <MQL 
Cimetidine N/A N/A N/A N/A N/A N/A 
Iopromide N/A N/A N/A N/A N/A N/A 
Buprenorphine 18.7 4.6 13.8 12.1 13.2 16.9 
Ephedrine/pseudoephedrin
e <MQL <MQL <MQL <MQL <MQL <MQL 
Norephedrine <MQL <MQL <MQL <MQL <MQL <MQL 
Azathioprine N/A N/A N/A N/A N/A N/A 
Methotrexate <MQL <MQL <MQL <MQL <MQL <MQL 
Ifosfamide N/A N/A N/A N/A N/A N/A 
Tamoxifen <MQL <MQL <MQL <MQL <MQL <MQL 
Imatinib 164.9 188.9 94.8 113.5 75.5 100.2 
Capecitabine <MQL <MQL <MQL <MQL <MQL <MQL 
Bicalutamide 71.5 54.1 40.4 53.7 44.5 36.1 
Ketamine 3.6 3.4 2.3 2.5 2.8 2.1 
Norketamine 1.1 1.2 0.6 0.7 0.7 0.7 
Venlafaxine 134.7 180.1 108.5 108.8 105.8 120.0 
Desmethylvenlafaxine 25.2 23.6 23.2 21.5 20.0 20.9 
Fluoxetine 238.8 242.3 168.2 172.7 169.1 171.3 
Norfluoxetine 133.7 123.1 77.2 73.8 68.0 72.4 
Sertraline 677.1 653.4 527.3 514.2 506.6 512.8 
Mirtazapine 80.5 78.0 60.7 60.6 60.4 74.3 
Citalopram 897.2 879.1 746.2 723.6 737.7 714.0 
Desmethylcitalopram 392.4 374.1 263.1 257.7 246.9 240.1 
Paroxetine 5.4 6.8 0.4 0.4 <MQL <MQL 
Duloxetine 25.9 25.0 16.6 13.8 11.1 12.8 
Amitriptyline 546.3 513.1 453.9 458.2 415.5 444.3 
Nortriptyline 86.7 82.2 55.8 52.8 48.9 53.0 
Norsertraline N/A N/A N/A N/A N/A N/A 
Carbamazepine 137.2 132.2 113.8 110.4 109.1 109.3 
Carbamazepine 10,11-
epoxide N/A N/A N/A N/A N/A N/A 
65 
 
 Day 1 Day 2 Day 3 
Compound A B A B A B 
10,11-Dihydro -10-
hydroxycarbamazepine <MQL <MQL <MQL <MQL <MQL <MQL 
Diltiazem N/A N/A N/A N/A N/A N/A 
Verapamil 60.6 58.5 46.8 45.8 46.2 48.6 
Temazepam <MQL <MQL <MQL <MQL <MQL <MQL 
Oxazepam <MQL <MQL <MQL <MQL <MQL <MQL 
Diazepam 4.9 4.0 3.9 4.5 3.9 4.3 
Quetiapine 18.4 18.0 13.9 13.9 13.1 26.7 
Risperidone <MQL <MQL <MQL <MQL <MQL <MQL 
Memantine <MQL <MQL <MQL <MQL <MQL <MQL 
Donepezil 8.4 8.1 <MQL <MQL <MQL <MQL 
Creatinine N/A N/A N/A N/A N/A N/A 
Nicotine 305.7 262.8 208.3 203.6 191.6 190.8 
Caffeine N/A N/A N/A N/A N/A N/A 
Cotinine 49.6 43.0 39.3 37.1 36.7 35.0 
1,7-dimethylxanthine N/A N/A N/A N/A N/A N/A 
Morphine 104.5 108.5 <MQL <MQL 22.6 17.2 
Dihydromorphine <MQL <MQL <MQL <MQL <MQL <MQL 
Normorphine <MQL <MQL <MQL <MQL <MQL <MQL 
Methadone 16.4 14.3 12.2 11.7 11.5 11.4 
EDDP 75.8 62.4 25.5 24.2 17.3 24.4 
Codeine 108.4 101.5 12.6 12.8 19.0 15.8 
Norcodeine <MQL <MQL <MQL <MQL <MQL <MQL 
Dihydrocodeine 30.8 29.2 23.0 22.1 22.6 21.0 
Tramadol 50.1 37.7 31.6 32.2 29.3 26.4 
N-desmethyltramadol 27.3 21.8 13.8 13.4 13.7 12.4 
O-desmethyltramadol N/A N/A N/A N/A N/A N/A 
Amphetamine <MQL <MQL <MQL <MQL <MQL <MQL 
Methamphetamine <MQL <MQL <MQL <MQL <MQL <MQL 
MDMA 7.8 7.1 5.0 5.7 5.6 5.4 
MDA N/A N/A N/A N/A N/A N/A 
Cocaine <MQL <MQL <MQL <MQL <MQL <MQL 
Benzoylecgonine <MQL <MQL <MQL <MQL <MQL <MQL 
Anhydroecgoninemethylest
er N/A N/A N/A N/A N/A N/A 
Cocaethylene <MQL <MQL <MQL <MQL <MQL <MQL 
Mephedrone <MQL <MQL <MQL <MQL <MQL <MQL 
MDPV <MQL <MQL <MQL <MQL <MQL <MQL 
Heroin <MQL <MQL <MQL <MQL <MQL <MQL 
6-acetylmorphine N/A N/A N/A N/A N/A N/A 
Thiamethoxam <MQL <MQL <MQL <MQL <MQL <MQL 
Imidacloprid <MQL <MQL <MQL <MQL <MQL <MQL 
Clothianidin <MQL <MQL <MQL <MQL <MQL <MQL 
Metazachlor <MQL <MQL <MQL <MQL <MQL <MQL 
Terbuthylazine <MQL <MQL <MQL <MQL <MQL <MQL 
Methiocarb <MQL 1.7 1.6 <MQL <MQL <MQL 
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 Day 1 Day 2 Day 3 
Compound A B A B A B 
Dichlofluanid N/A N/A N/A N/A N/A N/A 
Flufenacet <MQL 15.4 14.7 <MQL 14.0 14.7 
Oxadiazon <MQL <MQL <MQL <MQL <MQL <MQL 
Chlorpyrifos <MQL <MQL 93.8 <MQL <MQL <MQL 
Triallate <MQL <MQL <MQL <MQL <MQL <MQL 
Tylosin N/A N/A N/A N/A N/A N/A 
Sulfapyridine N/A N/A N/A N/A N/A N/A 
Sarafloxacin <MQL <MQL <MQL <MQL <MQL <MQL 
Ceftiofur <MQL <MQL <MQL <MQL <MQL <MQL 
Diazinon 17.4 <MQL <MQL 10.8 <MQL <MQL 
 
